Russia said on Tuesday that its Sputnik V vaccine against Covid-19 disease, developed by the Gamaleïa research center in Moscow, was 95% effective.
These are the preliminary results obtained on volunteers 42 days after the first dose injection, said in a statement this center, the Russian Ministry of Health and the Russian Sovereign Fund, involved in developing this vaccine.
However, they did not mention the number of cases used for the calculations.
The British laboratory AstraZeneca and the University of Oxford announced Monday that their vaccine was 70% effective on average.
For its part, the vaccine developed by the Pfizer-BioNTech alliance is 95% effective in preventing Covid-19, according to full results of their large-scale clinical trial, announced last week. The American company Moderna announced similar results (94.5% efficiency).
“The price of a dose of Sputnik V for the international market will be less than $ 10,” the Russian Sovereign Fund announced in a separate statement, specifying that vaccination for Russian citizens would be free.
The Sputnik V vaccine is currently in phase 3 of double-blind, randomized clinical trials – an experimental approach used in several disciplines – with 40,000 volunteers.